On August 30, 2018 ArQule, Inc. (Nasdaq: ARQL) reported that Paolo Pucci, CEO, and Dr. Brian Schwartz, CMO and Head of Research and Development, will participate in investor meetings and scientific panel discussions at the B. Riley FBR Healthcare Conference on September 4, 2018, at the New York Marriott East Side Hotel in New York City (Press release, ArQule, AUG 30, 2018, View Source [SID1234529189]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On August 30, 2018 ArQule, Inc. (Nasdaq: ARQL) reported that Paolo Pucci, CEO, Peter Lawrence, President and COO, Brian Schwartz, CMO and Head of R&D and Marc Schegerin, Senior Vice President and Head of Strategy, Finance and Communication, will participate in Citi’s 13th Annual Biotech Conference on September 6, 2018, at the Four Seasons Hotel in Boston, MA (Press release, ArQule, AUG 30, 2018, View Source [SID1234529188]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On August 30, 2018 Gilead Sciences, Inc. (Nasdaq: GILD) reported that John F. Milligan, PhD, Gilead’s President and Chief Executive Officer; Robin L. Washington, Gilead’s Executive Vice President and Chief Financial Officer; and John McHutchison, AO, MD, Gilead’s Chief Scientific Officer and Head of Research & Development, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York on Wednesday, September 12 at 11:05 a.m. Eastern Time (Press release, Gilead Sciences, AUG 30, 2018, View Source [SID1234529187]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The audio portion of the fireside chat will be accessible live through the company’s Investors page at www.gilead.com/investors. Please connect to the company’s website at least 15 minutes prior to the start of the presentation to ensure adequate time for any software download that may be required to listen to the webcast. The replay will be available for 14 days following the presentation.

On August 30, 2018 Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, reported that Jeff Goater, chief executive officer, and Vito Palombella, Ph.D., chief scientific officer, will participate in a fireside chat at the Baird 2018 Global Healthcare Conference (Press release, Surface Oncology, AUG 30, 2018, View Source [SID1234529186]). The presentation will take place on Thursday, September 6th, 2018 at 9:40AM ET at the Intercontinental New York Barclay Hotel, in New York, NY.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live audio and subsequent archived webcasts of the Company’s presentations will be accessible from the Company’s investor relations website, investors.surfaceoncology.com.

On August 30, 2018 Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, reported that it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC (Press release, Trillium Therapeutics, AUG 30, 2018, View Source;Renshaw-Global-Investment-Conference/default.aspx [SID1234529185]). The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presenter: Dr. Niclas Stiernholm, Chief Executive Officer
Date: September 5, 2018
Time: 4:15 pm (Eastern Time)
Location: Library (2nd floor)